 Adriana Weinberg
Concepts (811)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 97 | 2025 | 2719 | 10.660 |
Why?
| | Herpes Zoster Vaccine | 24 | 2024 | 162 | 9.500 |
Why?
| | Herpes Zoster | 32 | 2024 | 317 | 8.990 |
Why?
| | Herpesvirus 3, Human | 35 | 2024 | 331 | 6.870 |
Why?
| | Cytomegalovirus Infections | 28 | 2024 | 189 | 6.280 |
Why?
| | Influenza Vaccines | 29 | 2021 | 532 | 6.210 |
Why?
| | Immunity, Cellular | 34 | 2025 | 265 | 5.950 |
Why?
| | Antibodies, Viral | 43 | 2024 | 601 | 5.620 |
Why?
| | T-Lymphocytes, Regulatory | 15 | 2025 | 373 | 5.000 |
Why?
| | Cytomegalovirus | 27 | 2024 | 154 | 4.570 |
Why?
| | Pregnancy Complications, Infectious | 24 | 2023 | 367 | 4.540 |
Why?
| | Influenza, Human | 27 | 2021 | 601 | 4.200 |
Why?
| | Antiretroviral Therapy, Highly Active | 22 | 2017 | 267 | 2.990 |
Why?
| | Influenza A Virus, H1N1 Subtype | 13 | 2021 | 146 | 2.700 |
Why?
| | Anti-HIV Agents | 18 | 2023 | 754 | 2.700 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2025 | 69 | 2.690 |
Why?
| | Pneumococcal Infections | 4 | 2022 | 110 | 2.640 |
Why?
| | T-Lymphocyte Subsets | 10 | 2019 | 412 | 2.590 |
Why?
| | T-Lymphocytes | 22 | 2020 | 1933 | 2.580 |
Why?
| | Immunologic Memory | 14 | 2020 | 349 | 2.560 |
Why?
| | Vaccines, Attenuated | 22 | 2024 | 125 | 2.460 |
Why?
| | Leukocytes, Mononuclear | 16 | 2025 | 545 | 2.430 |
Why?
| | CD4-Positive T-Lymphocytes | 28 | 2023 | 1056 | 2.250 |
Why?
| | Respiratory Tract Infections | 7 | 2025 | 375 | 2.200 |
Why?
| | Vaccination | 22 | 2023 | 1347 | 1.770 |
Why?
| | Antiviral Agents | 17 | 2023 | 712 | 1.670 |
Why?
| | Humans | 231 | 2025 | 129266 | 1.670 |
Why?
| | Chickenpox | 7 | 2023 | 80 | 1.660 |
Why?
| | Interferon-gamma | 19 | 2022 | 772 | 1.630 |
Why?
| | Drug Resistance, Viral | 14 | 2017 | 110 | 1.540 |
Why?
| | Female | 159 | 2025 | 68551 | 1.520 |
Why?
| | HIV | 8 | 2022 | 226 | 1.510 |
Why?
| | CD8-Positive T-Lymphocytes | 12 | 2019 | 857 | 1.450 |
Why?
| | Chickenpox Vaccine | 10 | 2023 | 71 | 1.430 |
Why?
| | Virus Diseases | 4 | 2018 | 210 | 1.420 |
Why?
| | Pregnancy | 42 | 2025 | 6390 | 1.380 |
Why?
| | Tetanus Toxoid | 4 | 2021 | 37 | 1.370 |
Why?
| | Virus Shedding | 6 | 2017 | 48 | 1.340 |
Why?
| | Infectious Disease Transmission, Vertical | 10 | 2023 | 170 | 1.330 |
Why?
| | Infant | 41 | 2025 | 8975 | 1.310 |
Why?
| | Influenza A virus | 9 | 2013 | 100 | 1.270 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 9 | 2009 | 28 | 1.250 |
Why?
| | Influenza B virus | 9 | 2017 | 37 | 1.240 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 120 | 1.230 |
Why?
| | Adult | 98 | 2025 | 35495 | 1.230 |
Why?
| | Hepatitis A Vaccines | 5 | 2020 | 15 | 1.220 |
Why?
| | DNA, Viral | 12 | 2018 | 349 | 1.200 |
Why?
| | Antibodies, Bacterial | 5 | 2022 | 137 | 1.190 |
Why?
| | B-Lymphocytes | 7 | 2021 | 815 | 1.160 |
Why?
| | Dermatitis, Atopic | 5 | 2020 | 319 | 1.150 |
Why?
| | Adjuvants, Immunologic | 8 | 2021 | 221 | 1.150 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2023 | 99 | 1.140 |
Why?
| | Male | 121 | 2025 | 63512 | 1.140 |
Why?
| | HIV-1 | 13 | 2019 | 836 | 1.080 |
Why?
| | CD4 Lymphocyte Count | 17 | 2019 | 266 | 1.070 |
Why?
| | Antibody Formation | 7 | 2023 | 291 | 1.050 |
Why?
| | Hemagglutination Inhibition Tests | 14 | 2021 | 38 | 1.050 |
Why?
| | Anti-Retroviral Agents | 8 | 2023 | 231 | 1.020 |
Why?
| | Gastrointestinal Microbiome | 2 | 2025 | 640 | 1.020 |
Why?
| | Pneumococcal Vaccines | 3 | 2022 | 140 | 1.010 |
Why?
| | Lymphocyte Activation | 25 | 2020 | 1109 | 1.010 |
Why?
| | Breast Feeding | 4 | 2023 | 423 | 0.990 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2023 | 572 | 0.950 |
Why?
| | Interleukin-2 | 12 | 2022 | 437 | 0.950 |
Why?
| | Vaccines, Synthetic | 6 | 2023 | 126 | 0.940 |
Why?
| | Viral Load | 18 | 2023 | 448 | 0.940 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 52 | 0.930 |
Why?
| | Vaccines, Inactivated | 10 | 2017 | 68 | 0.930 |
Why?
| | Infant, Newborn | 24 | 2025 | 5736 | 0.930 |
Why?
| | Enzyme-Linked Immunospot Assay | 6 | 2018 | 36 | 0.920 |
Why?
| | Viremia | 9 | 2021 | 131 | 0.920 |
Why?
| | Child, Preschool | 34 | 2025 | 10459 | 0.870 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 68 | 0.870 |
Why?
| | Papillomavirus Vaccines | 3 | 2018 | 232 | 0.850 |
Why?
| | Child | 53 | 2025 | 20785 | 0.850 |
Why?
| | Immune Reconstitution | 1 | 2023 | 6 | 0.850 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2013 | 94 | 0.850 |
Why?
| | Environmental Exposure | 2 | 2018 | 462 | 0.840 |
Why?
| | Double-Blind Method | 17 | 2021 | 1875 | 0.770 |
Why?
| | Middle Aged | 63 | 2024 | 31090 | 0.770 |
Why?
| | Herpesvirus 1, Human | 3 | 2016 | 86 | 0.770 |
Why?
| | Adolescent | 53 | 2025 | 20313 | 0.770 |
Why?
| | Receptors, Tumor Necrosis Factor | 8 | 2001 | 161 | 0.770 |
Why?
| | Cytokines | 12 | 2025 | 2013 | 0.750 |
Why?
| | Aged | 42 | 2024 | 22032 | 0.740 |
Why?
| | Young Adult | 29 | 2023 | 12391 | 0.740 |
Why?
| | Polymerase Chain Reaction | 12 | 2023 | 1036 | 0.730 |
Why?
| | Orthomyxoviridae | 3 | 2017 | 40 | 0.730 |
Why?
| | Aged, 80 and over | 18 | 2022 | 7055 | 0.720 |
Why?
| | Latent Tuberculosis | 1 | 2021 | 67 | 0.700 |
Why?
| | DNA-Directed DNA Polymerase | 4 | 2008 | 44 | 0.690 |
Why?
| | Viral Proteins | 5 | 2012 | 327 | 0.680 |
Why?
| | Vitamin D | 2 | 2024 | 385 | 0.680 |
Why?
| | Herpesvirus 4, Human | 8 | 2014 | 154 | 0.670 |
Why?
| | Rotavirus Infections | 2 | 2017 | 45 | 0.660 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 49 | 0.660 |
Why?
| | Immunosuppressive Agents | 7 | 2014 | 854 | 0.640 |
Why?
| | Viral Envelope Proteins | 2 | 2021 | 81 | 0.640 |
Why?
| | Antibodies, Neutralizing | 7 | 2021 | 265 | 0.630 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2016 | 35 | 0.620 |
Why?
| | Tuberculosis | 5 | 2023 | 273 | 0.620 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2019 | 34 | 0.620 |
Why?
| | Isoniazid | 5 | 2023 | 63 | 0.600 |
Why?
| | Paramyxoviridae Infections | 2 | 2011 | 12 | 0.600 |
Why?
| | Simplexvirus | 9 | 2016 | 80 | 0.600 |
Why?
| | Human papillomavirus 18 | 1 | 2018 | 15 | 0.590 |
Why?
| | Mycobacterium tuberculosis | 1 | 2021 | 309 | 0.590 |
Why?
| | Cryopreservation | 2 | 2010 | 92 | 0.590 |
Why?
| | Human papillomavirus 16 | 1 | 2018 | 34 | 0.580 |
Why?
| | Immunocompromised Host | 9 | 2019 | 198 | 0.580 |
Why?
| | Hepatitis A Antibodies | 2 | 2009 | 3 | 0.580 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2019 | 123 | 0.580 |
Why?
| | Th1 Cells | 1 | 2018 | 137 | 0.560 |
Why?
| | Hospitalization | 6 | 2021 | 2052 | 0.560 |
Why?
| | Lymphocyte Subsets | 2 | 2015 | 84 | 0.560 |
Why?
| | Immunoconjugates | 2 | 2013 | 103 | 0.550 |
Why?
| | Flow Cytometry | 11 | 2019 | 1155 | 0.550 |
Why?
| | Antigens, Viral | 8 | 2017 | 178 | 0.550 |
Why?
| | Age Factors | 9 | 2019 | 3140 | 0.550 |
Why?
| | Immunization, Secondary | 6 | 2017 | 87 | 0.540 |
Why?
| | Mutation | 7 | 2009 | 3710 | 0.540 |
Why?
| | Premature Birth | 2 | 2019 | 314 | 0.530 |
Why?
| | Herpesviridae Infections | 5 | 2013 | 141 | 0.520 |
Why?
| | Acyclovir | 6 | 2012 | 99 | 0.520 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 1999 | 57 | 0.520 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 351 | 0.500 |
Why?
| | Viral Vaccines | 4 | 2014 | 94 | 0.500 |
Why?
| | Herpes Simplex | 4 | 2016 | 92 | 0.490 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2011 | 169 | 0.490 |
Why?
| | Case-Control Studies | 13 | 2020 | 3377 | 0.490 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2005 | 43 | 0.470 |
Why?
| | Central Nervous System Viral Diseases | 3 | 2004 | 73 | 0.470 |
Why?
| | Contraceptive Agents, Female | 1 | 2016 | 78 | 0.470 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 74 | 0.460 |
Why?
| | Immunoglobulin G | 7 | 2021 | 848 | 0.460 |
Why?
| | Immunoassay | 5 | 2017 | 107 | 0.450 |
Why?
| | Injections, Intramuscular | 4 | 2017 | 115 | 0.450 |
Why?
| | RNA, Viral | 8 | 2019 | 619 | 0.450 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 94 | 0.450 |
Why?
| | Foscarnet | 6 | 2008 | 19 | 0.440 |
Why?
| | Transplant Recipients | 3 | 2024 | 162 | 0.430 |
Why?
| | Immunophenotyping | 5 | 2019 | 310 | 0.420 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1688 | 0.420 |
Why?
| | Antigen-Presenting Cells | 4 | 2022 | 151 | 0.420 |
Why?
| | B-Lymphocytes, Regulatory | 1 | 2013 | 3 | 0.410 |
Why?
| | Postpartum Period | 5 | 2022 | 332 | 0.410 |
Why?
| | CD4 Antigens | 2 | 2011 | 138 | 0.410 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2020 | 43 | 0.410 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 434 | 0.400 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2020 | 83 | 0.400 |
Why?
| | Immune Tolerance | 2 | 2013 | 355 | 0.400 |
Why?
| | Cohort Studies | 11 | 2023 | 5409 | 0.390 |
Why?
| | Alphapapillomavirus | 1 | 2012 | 40 | 0.390 |
Why?
| | Candida | 3 | 2010 | 37 | 0.390 |
Why?
| | Cell Proliferation | 6 | 2020 | 2375 | 0.390 |
Why?
| | Hepatitis A | 1 | 2012 | 25 | 0.390 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 63 | 0.390 |
Why?
| | Skin | 1 | 2017 | 726 | 0.380 |
Why?
| | Polysaccharides | 2 | 2022 | 86 | 0.380 |
Why?
| | Placebos | 5 | 2017 | 201 | 0.380 |
Why?
| | CD28 Antigens | 3 | 2009 | 48 | 0.380 |
Why?
| | Retrospective Studies | 21 | 2024 | 14461 | 0.370 |
Why?
| | Metapneumovirus | 1 | 2011 | 14 | 0.370 |
Why?
| | Transplantation | 1 | 2011 | 31 | 0.370 |
Why?
| | Contraceptive Agents | 1 | 2012 | 65 | 0.370 |
Why?
| | Herpesvirus 2, Human | 2 | 2012 | 28 | 0.360 |
Why?
| | Pregnancy Outcome | 7 | 2021 | 389 | 0.360 |
Why?
| | Lymphocyte Count | 4 | 2019 | 148 | 0.360 |
Why?
| | Lymphoproliferative Disorders | 1 | 2011 | 54 | 0.360 |
Why?
| | Blood | 2 | 2009 | 105 | 0.350 |
Why?
| | Nucleosides | 1 | 2010 | 27 | 0.350 |
Why?
| | Drug Therapy, Combination | 6 | 2019 | 1040 | 0.350 |
Why?
| | Antitubercular Agents | 3 | 2023 | 200 | 0.340 |
Why?
| | Streptococcus pneumoniae | 2 | 2022 | 159 | 0.340 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 232 | 0.340 |
Why?
| | Immunoglobulin A | 4 | 2017 | 200 | 0.330 |
Why?
| | Adaptive Immunity | 2 | 2017 | 161 | 0.330 |
Why?
| | Cytosine | 3 | 2008 | 46 | 0.330 |
Why?
| | Antidepressive Agents | 3 | 2021 | 228 | 0.330 |
Why?
| | Glycoproteins | 2 | 2023 | 338 | 0.330 |
Why?
| | Nucleotides | 1 | 2010 | 122 | 0.330 |
Why?
| | Membrane Glycoproteins | 4 | 2001 | 476 | 0.330 |
Why?
| | Refrigeration | 1 | 2009 | 11 | 0.330 |
Why?
| | Immunity, Humoral | 2 | 2021 | 118 | 0.320 |
Why?
| | Astrocytes | 1 | 2011 | 196 | 0.320 |
Why?
| | Organophosphonates | 3 | 2008 | 92 | 0.320 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 833 | 0.320 |
Why?
| | T-Lymphocytes, Helper-Inducer | 5 | 1994 | 135 | 0.310 |
Why?
| | Freezing | 1 | 2009 | 85 | 0.310 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 18 | 0.310 |
Why?
| | Coculture Techniques | 2 | 2025 | 223 | 0.310 |
Why?
| | Tetanus | 2 | 2009 | 25 | 0.310 |
Why?
| | Time Factors | 18 | 2017 | 6543 | 0.300 |
Why?
| | Follow-Up Studies | 15 | 2022 | 4887 | 0.300 |
Why?
| | Lopinavir | 3 | 2023 | 30 | 0.300 |
Why?
| | Benzoxazines | 3 | 2023 | 30 | 0.300 |
Why?
| | Interleukin-10 | 3 | 2022 | 300 | 0.300 |
Why?
| | Longitudinal Studies | 8 | 2019 | 2715 | 0.290 |
Why?
| | Immunogenicity, Vaccine | 4 | 2021 | 27 | 0.290 |
Why?
| | Specimen Handling | 1 | 2009 | 162 | 0.290 |
Why?
| | Herpesvirus 7, Human | 2 | 2005 | 6 | 0.290 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 100 | 0.290 |
Why?
| | Glioblastoma | 1 | 2011 | 322 | 0.290 |
Why?
| | Herpesvirus 6, Human | 2 | 2005 | 13 | 0.290 |
Why?
| | Norgestrel | 1 | 2007 | 2 | 0.280 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 947 | 0.280 |
Why?
| | Interleukins | 2 | 2008 | 241 | 0.280 |
Why?
| | Incidence | 9 | 2023 | 2636 | 0.270 |
Why?
| | Biomarkers | 7 | 2021 | 3968 | 0.270 |
Why?
| | Apoptosis | 6 | 2011 | 2499 | 0.270 |
Why?
| | Antigens, CD | 5 | 2017 | 489 | 0.270 |
Why?
| | Lung Transplantation | 4 | 2002 | 289 | 0.260 |
Why?
| | Prospective Studies | 12 | 2021 | 7123 | 0.260 |
Why?
| | Nucleic Acid Hybridization | 2 | 2006 | 189 | 0.260 |
Why?
| | Killer Cells, Natural | 3 | 2009 | 427 | 0.260 |
Why?
| | Coinfection | 2 | 2019 | 131 | 0.250 |
Why?
| | Pregnant Women | 3 | 2021 | 114 | 0.250 |
Why?
| | Fibroblasts | 4 | 2025 | 948 | 0.250 |
Why?
| | Bone Marrow Transplantation | 2 | 2005 | 275 | 0.240 |
Why?
| | Ritonavir | 2 | 2016 | 73 | 0.240 |
Why?
| | A549 Cells | 1 | 2025 | 59 | 0.230 |
Why?
| | Dexamethasone | 1 | 2007 | 350 | 0.230 |
Why?
| | Receptors, OX40 | 8 | 2001 | 15 | 0.230 |
Why?
| | Cell Survival | 5 | 2010 | 1075 | 0.230 |
Why?
| | Virus Replication | 5 | 2017 | 450 | 0.230 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 7 | 0.230 |
Why?
| | Paramyxoviridae | 1 | 2004 | 2 | 0.230 |
Why?
| | Autoimmune Diseases | 3 | 2014 | 426 | 0.230 |
Why?
| | Milk, Human | 2 | 2023 | 151 | 0.220 |
Why?
| | Forkhead Transcription Factors | 3 | 2011 | 184 | 0.220 |
Why?
| | BCG Vaccine | 2 | 2023 | 24 | 0.220 |
Why?
| | Lymphokines | 4 | 1994 | 127 | 0.220 |
Why?
| | Ganciclovir | 4 | 2008 | 52 | 0.220 |
Why?
| | Papillomavirus Infections | 2 | 2018 | 297 | 0.220 |
Why?
| | Estradiol | 1 | 2007 | 494 | 0.220 |
Why?
| | Immunity, Innate | 1 | 2009 | 803 | 0.220 |
Why?
| | Brazil | 2 | 2021 | 154 | 0.220 |
Why?
| | Immunity | 2 | 2020 | 138 | 0.210 |
Why?
| | Cholecalciferol | 1 | 2024 | 56 | 0.210 |
Why?
| | Orthomyxoviridae Infections | 1 | 2004 | 67 | 0.210 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2023 | 12 | 0.210 |
Why?
| | Myelin Basic Protein | 4 | 1998 | 45 | 0.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 252 | 0.210 |
Why?
| | Long-Term Care | 1 | 2024 | 92 | 0.210 |
Why?
| | Maternal-Fetal Exchange | 2 | 2016 | 161 | 0.210 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2023 | 227 | 0.210 |
Why?
| | Kaposi Varicelliform Eruption | 3 | 2011 | 21 | 0.210 |
Why?
| | Heart Transplantation | 10 | 2001 | 721 | 0.210 |
Why?
| | United States | 9 | 2024 | 13826 | 0.200 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 15 | 0.200 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 2013 | 3628 | 0.200 |
Why?
| | Transforming Growth Factor beta | 3 | 2009 | 455 | 0.200 |
Why?
| | Isoxazoles | 2 | 2013 | 55 | 0.200 |
Why?
| | Risk Factors | 18 | 2024 | 9745 | 0.200 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 64 | 0.200 |
Why?
| | Lamivudine | 2 | 2015 | 61 | 0.200 |
Why?
| | Zidovudine | 2 | 2015 | 78 | 0.200 |
Why?
| | Herpes Genitalis | 2 | 2012 | 16 | 0.200 |
Why?
| | HIV Integrase Inhibitors | 1 | 2023 | 69 | 0.190 |
Why?
| | South Africa | 6 | 2020 | 192 | 0.190 |
Why?
| | Genes, Immediate-Early | 1 | 2002 | 20 | 0.190 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 87 | 0.190 |
Why?
| | Cyclopropanes | 2 | 2020 | 89 | 0.190 |
Why?
| | Lymphocytosis | 1 | 2021 | 10 | 0.190 |
Why?
| | Central Nervous System Diseases | 1 | 2002 | 68 | 0.190 |
Why?
| | Genes, Viral | 1 | 2002 | 82 | 0.190 |
Why?
| | Alkynes | 2 | 2020 | 55 | 0.190 |
Why?
| | Antigens, Differentiation | 1 | 2001 | 81 | 0.190 |
Why?
| | Tuberculin Test | 1 | 2021 | 36 | 0.190 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2002 | 220 | 0.190 |
Why?
| | Interferon-gamma Release Tests | 1 | 2021 | 32 | 0.190 |
Why?
| | Biliary Atresia | 1 | 2023 | 161 | 0.190 |
Why?
| | Organ Transplantation | 1 | 2024 | 228 | 0.180 |
Why?
| | Maternal Exposure | 1 | 2023 | 177 | 0.180 |
Why?
| | Cells, Cultured | 11 | 2010 | 4077 | 0.180 |
Why?
| | Phenotype | 7 | 2009 | 3074 | 0.180 |
Why?
| | RNA, Messenger | 9 | 2011 | 2703 | 0.180 |
Why?
| | Atazanavir Sulfate | 2 | 2023 | 41 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 64 | 0.180 |
Why?
| | Medication Therapy Management | 1 | 2021 | 72 | 0.180 |
Why?
| | Evolution, Molecular | 1 | 2005 | 464 | 0.180 |
Why?
| | Immunoglobulins | 2 | 2017 | 160 | 0.170 |
Why?
| | Sensitivity and Specificity | 5 | 2009 | 1839 | 0.170 |
Why?
| | Virus Activation | 3 | 2013 | 88 | 0.170 |
Why?
| | North America | 2 | 2023 | 291 | 0.170 |
Why?
| | Receptors, Immunologic | 2 | 2000 | 216 | 0.170 |
Why?
| | HIV Seronegativity | 1 | 2020 | 25 | 0.170 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2002 | 200 | 0.170 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 521 | 0.170 |
Why?
| | Virus Cultivation | 3 | 2005 | 28 | 0.170 |
Why?
| | Treatment Outcome | 16 | 2017 | 10202 | 0.170 |
Why?
| | Inflammation | 4 | 2019 | 2737 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 534 | 0.160 |
Why?
| | Postoperative Complications | 14 | 2001 | 2473 | 0.160 |
Why?
| | Heart-Assist Devices | 8 | 2000 | 539 | 0.160 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 51 | 0.160 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.160 |
Why?
| | Eicosanoids | 1 | 2019 | 57 | 0.160 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2017 | 15 | 0.160 |
Why?
| | Survival Analysis | 6 | 2018 | 1269 | 0.160 |
Why?
| | Abatacept | 2 | 2013 | 46 | 0.150 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 155 | 0.150 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2016 | 82 | 0.150 |
Why?
| | Cholera Toxin | 1 | 2018 | 31 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 630 | 0.150 |
Why?
| | Saliva | 2 | 2010 | 210 | 0.150 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 68 | 0.150 |
Why?
| | Depressive Disorder, Major | 2 | 2013 | 345 | 0.150 |
Why?
| | Delayed-Action Preparations | 2 | 2016 | 172 | 0.150 |
Why?
| | Cell Movement | 2 | 2001 | 944 | 0.150 |
Why?
| | Genotype | 6 | 2020 | 1835 | 0.140 |
Why?
| | Latin America | 1 | 2018 | 87 | 0.140 |
Why?
| | Vaccination Coverage | 1 | 2018 | 79 | 0.140 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 6 | 0.140 |
Why?
| | CD4-CD8 Ratio | 2 | 2008 | 22 | 0.140 |
Why?
| | Coronary Artery Bypass | 4 | 2001 | 224 | 0.140 |
Why?
| | Cell Line | 5 | 2009 | 2779 | 0.140 |
Why?
| | Injections, Intradermal | 1 | 2017 | 13 | 0.140 |
Why?
| | Injections, Subcutaneous | 2 | 2016 | 147 | 0.140 |
Why?
| | Nervous System Diseases | 1 | 2020 | 252 | 0.140 |
Why?
| | Placenta | 2 | 2021 | 723 | 0.140 |
Why?
| | Paralysis | 1 | 2017 | 69 | 0.130 |
Why?
| | Seroconversion | 1 | 2017 | 46 | 0.130 |
Why?
| | Arm | 1 | 2017 | 107 | 0.130 |
Why?
| | Africa | 1 | 2017 | 99 | 0.130 |
Why?
| | Seizures | 1 | 2020 | 401 | 0.130 |
Why?
| | Kinetics | 3 | 2010 | 1644 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1004 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.130 |
Why?
| | Aging | 3 | 2017 | 1774 | 0.130 |
Why?
| | Adoptive Transfer | 3 | 2002 | 218 | 0.130 |
Why?
| | Monocytes | 1 | 2019 | 551 | 0.130 |
Why?
| | Animals | 21 | 2011 | 35309 | 0.130 |
Why?
| | Colorado | 2 | 2023 | 4406 | 0.130 |
Why?
| | Cross Reactions | 2 | 2014 | 132 | 0.130 |
Why?
| | Demography | 2 | 2018 | 279 | 0.120 |
Why?
| | Comorbidity | 2 | 2019 | 1544 | 0.120 |
Why?
| | RNA | 1 | 2022 | 880 | 0.120 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 831 | 0.120 |
Why?
| | Contraceptives, Oral, Synthetic | 1 | 2015 | 1 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 67 | 0.120 |
Why?
| | Nasal Lavage Fluid | 2 | 2005 | 14 | 0.120 |
Why?
| | Computational Biology | 1 | 2019 | 595 | 0.120 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1416 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 110 | 0.110 |
Why?
| | Neutropenia | 1 | 2015 | 136 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1481 | 0.110 |
Why?
| | Virus Latency | 2 | 2013 | 84 | 0.110 |
Why?
| | Skin Diseases | 1 | 2016 | 143 | 0.110 |
Why?
| | Immunoenzyme Techniques | 2 | 2006 | 214 | 0.110 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 88 | 0.110 |
Why?
| | Seroepidemiologic Studies | 2 | 2024 | 156 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1497 | 0.110 |
Why?
| | Herpesvirus 8, Human | 2 | 2005 | 60 | 0.110 |
Why?
| | Feces | 1 | 2017 | 441 | 0.110 |
Why?
| | Physical Fitness | 1 | 2015 | 203 | 0.110 |
Why?
| | Anemia | 1 | 2015 | 160 | 0.110 |
Why?
| | Graft Rejection | 5 | 2001 | 598 | 0.110 |
Why?
| | Base Sequence | 5 | 2017 | 2146 | 0.110 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 11 | 0.110 |
Why?
| | Progesterone | 2 | 2015 | 245 | 0.110 |
Why?
| | Thrombocytopenia | 1 | 2015 | 186 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 874 | 0.100 |
Why?
| | Leukocyte Common Antigens | 2 | 2009 | 82 | 0.100 |
Why?
| | Epitopes | 2 | 2009 | 470 | 0.100 |
Why?
| | Polyomavirus Infections | 1 | 2013 | 27 | 0.100 |
Why?
| | Tumor Virus Infections | 1 | 2013 | 46 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 186 | 0.100 |
Why?
| | Mothers | 1 | 2019 | 730 | 0.100 |
Why?
| | Depression | 1 | 2021 | 1306 | 0.100 |
Why?
| | OX40 Ligand | 4 | 2001 | 10 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2019 | 1266 | 0.100 |
Why?
| | Proctitis | 1 | 2012 | 6 | 0.100 |
Why?
| | Oxadiazoles | 1 | 2012 | 33 | 0.100 |
Why?
| | Communicable Diseases | 1 | 2014 | 147 | 0.100 |
Why?
| | HIV Seropositivity | 1 | 2013 | 119 | 0.100 |
Why?
| | Rats, Inbred Lew | 4 | 1998 | 111 | 0.100 |
Why?
| | Aprotinin | 3 | 1997 | 9 | 0.100 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 4 | 0.100 |
Why?
| | DNA Primase | 1 | 2012 | 45 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 110 | 0.100 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2011 | 10 | 0.090 |
Why?
| | Viral Plaque Assay | 3 | 2006 | 29 | 0.090 |
Why?
| | L-Selectin | 2 | 2009 | 25 | 0.090 |
Why?
| | Guanine | 3 | 2006 | 76 | 0.090 |
Why?
| | Histocompatibility Testing | 3 | 2001 | 120 | 0.090 |
Why?
| | CD8 Antigens | 1 | 2011 | 76 | 0.090 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 43 | 0.090 |
Why?
| | Length of Stay | 3 | 2014 | 1120 | 0.090 |
Why?
| | Ribavirin | 1 | 2011 | 91 | 0.090 |
Why?
| | Immunization Schedule | 3 | 2020 | 197 | 0.090 |
Why?
| | Fluorescent Antibody Technique | 2 | 2016 | 376 | 0.090 |
Why?
| | DNA Helicases | 1 | 2012 | 149 | 0.090 |
Why?
| | Motor Activity | 1 | 2015 | 675 | 0.090 |
Why?
| | Parturition | 1 | 2011 | 70 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2005 | 1949 | 0.090 |
Why?
| | Logistic Models | 5 | 2010 | 1985 | 0.080 |
Why?
| | Algorithms | 3 | 2021 | 1613 | 0.080 |
Why?
| | Menstrual Cycle | 1 | 2011 | 121 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Fetal Blood | 2 | 2019 | 317 | 0.080 |
Why?
| | Herpes Simplex Virus Vaccines | 1 | 2009 | 4 | 0.080 |
Why?
| | Granzymes | 1 | 2009 | 47 | 0.080 |
Why?
| | Immune System | 2 | 2008 | 175 | 0.080 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 7 | 0.080 |
Why?
| | Human Experimentation | 1 | 2009 | 12 | 0.080 |
Why?
| | Neuralgia, Postherpetic | 1 | 2009 | 40 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2011 | 230 | 0.080 |
Why?
| | Cost of Illness | 1 | 2011 | 277 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 159 | 0.080 |
Why?
| | Plasma | 2 | 2018 | 205 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 182 | 0.080 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2008 | 15 | 0.080 |
Why?
| | Nasal Mucosa | 1 | 2009 | 107 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1202 | 0.080 |
Why?
| | Infant Mortality | 2 | 2019 | 103 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 827 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2011 | 505 | 0.080 |
Why?
| | Botswana | 2 | 2019 | 8 | 0.070 |
Why?
| | Genetic Variation | 2 | 2011 | 938 | 0.070 |
Why?
| | Betaherpesvirinae | 1 | 2008 | 1 | 0.070 |
Why?
| | Exodeoxyribonucleases | 1 | 2008 | 24 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 84 | 0.070 |
Why?
| | Sarcoma | 1 | 2010 | 176 | 0.070 |
Why?
| | Interleukin-15 | 1 | 2008 | 82 | 0.070 |
Why?
| | Rats | 5 | 1998 | 5482 | 0.070 |
Why?
| | Cyclosporine | 2 | 2001 | 263 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2008 | 118 | 0.070 |
Why?
| | Trypan Blue | 1 | 2007 | 6 | 0.070 |
Why?
| | Didanosine | 1 | 2007 | 13 | 0.070 |
Why?
| | Mice | 11 | 2011 | 16915 | 0.070 |
Why?
| | Thymus Gland | 1 | 2008 | 308 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 758 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 336 | 0.070 |
Why?
| | Gene Expression | 3 | 2006 | 1466 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1365 | 0.070 |
Why?
| | Veterans | 1 | 2018 | 1374 | 0.070 |
Why?
| | Quality Control | 1 | 2007 | 163 | 0.070 |
Why?
| | Pneumonia | 1 | 2013 | 616 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 285 | 0.070 |
Why?
| | In Vitro Techniques | 3 | 2006 | 1085 | 0.070 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 278 | 0.070 |
Why?
| | Vero Cells | 1 | 2006 | 65 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 86 | 0.070 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 91 | 0.070 |
Why?
| | Drug Interactions | 2 | 2020 | 393 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2007 | 165 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4057 | 0.060 |
Why?
| | Risk Assessment | 2 | 2014 | 3232 | 0.060 |
Why?
| | Hemostatics | 2 | 1997 | 49 | 0.060 |
Why?
| | Opportunistic Infections | 2 | 2014 | 46 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 841 | 0.060 |
Why?
| | Hemadsorption | 1 | 2005 | 1 | 0.060 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2005 | 14 | 0.060 |
Why?
| | Signal Transduction | 2 | 2000 | 4926 | 0.060 |
Why?
| | Tumor Necrosis Factors | 3 | 2001 | 10 | 0.060 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2006 | 157 | 0.060 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 173 | 0.060 |
Why?
| | Gene Products, pol | 1 | 2005 | 6 | 0.060 |
Why?
| | Annexin A5 | 1 | 2004 | 23 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2017 | 72 | 0.060 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2004 | 50 | 0.060 |
Why?
| | Antigens | 2 | 2008 | 356 | 0.060 |
Why?
| | Meningitis, Viral | 1 | 2004 | 21 | 0.060 |
Why?
| | Emtricitabine | 2 | 2021 | 168 | 0.060 |
Why?
| | Parainfluenza Virus 2, Human | 1 | 2004 | 3 | 0.060 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 2004 | 3 | 0.060 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2004 | 5 | 0.060 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 55 | 0.060 |
Why?
| | Sarcoma, Kaposi | 2 | 2003 | 76 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 336 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 2 | 2001 | 295 | 0.060 |
Why?
| | Transplantation, Homologous | 2 | 2002 | 400 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2004 | 26 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2005 | 299 | 0.050 |
Why?
| | Survival Rate | 8 | 2001 | 1869 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 4 | 0.050 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3202 | 0.050 |
Why?
| | Hospital Mortality | 4 | 2001 | 846 | 0.050 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2010 | 592 | 0.050 |
Why?
| | Rilpivirine | 1 | 2023 | 7 | 0.050 |
Why?
| | HLA-DR Antigens | 3 | 2001 | 223 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2023 | 45 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 89 | 0.050 |
Why?
| | Darunavir | 1 | 2023 | 18 | 0.050 |
Why?
| | Bronchiolitis Obliterans | 2 | 2001 | 68 | 0.050 |
Why?
| | Herpes Labialis | 1 | 2003 | 8 | 0.050 |
Why?
| | DNA Primers | 3 | 2009 | 510 | 0.050 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| | Pregnancy Trimester, First | 1 | 2023 | 137 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 336 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 644 | 0.050 |
Why?
| | Risk | 1 | 2005 | 854 | 0.050 |
Why?
| | Parapsychology | 1 | 2001 | 1 | 0.050 |
Why?
| | Transfection | 2 | 2002 | 915 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 192 | 0.050 |
Why?
| | Electromagnetic Fields | 1 | 2001 | 23 | 0.050 |
Why?
| | Zimbabwe | 2 | 2017 | 53 | 0.050 |
Why?
| | Ovalbumin | 1 | 2001 | 178 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2003 | 350 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2001 | 87 | 0.050 |
Why?
| | B7-1 Antigen | 2 | 1998 | 61 | 0.050 |
Why?
| | Lymphoma | 1 | 2002 | 196 | 0.050 |
Why?
| | Rituximab | 2 | 2013 | 164 | 0.050 |
Why?
| | Photography | 1 | 2001 | 93 | 0.050 |
Why?
| | Cobicistat | 1 | 2021 | 5 | 0.050 |
Why?
| | Receptors, CXCR5 | 1 | 2021 | 20 | 0.050 |
Why?
| | Antibody Affinity | 1 | 2021 | 59 | 0.050 |
Why?
| | Glioma | 1 | 2005 | 347 | 0.050 |
Why?
| | Models, Statistical | 1 | 2005 | 623 | 0.050 |
Why?
| | Prostheses and Implants | 3 | 1996 | 130 | 0.040 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 48 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2020 | 7 | 0.040 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2020 | 5 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2020 | 9 | 0.040 |
Why?
| | Pre-Eclampsia | 1 | 2023 | 187 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2002 | 130 | 0.040 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2001 | 107 | 0.040 |
Why?
| | Spinal Cord | 2 | 1994 | 353 | 0.040 |
Why?
| | Central Nervous System Neoplasms | 1 | 2002 | 146 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2020 | 117 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 286 | 0.040 |
Why?
| | Surface Properties | 1 | 2001 | 397 | 0.040 |
Why?
| | DNA | 2 | 2006 | 1396 | 0.040 |
Why?
| | Heart Failure | 3 | 1999 | 2135 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 142 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2001 | 320 | 0.040 |
Why?
| | Trans-Activators | 1 | 2002 | 388 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 28 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 2001 | 164 | 0.040 |
Why?
| | Hemodynamics | 3 | 2001 | 1090 | 0.040 |
Why?
| | Antibodies | 1 | 2001 | 398 | 0.040 |
Why?
| | Coronary Disease | 2 | 2001 | 385 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5050 | 0.040 |
Why?
| | California | 2 | 2015 | 400 | 0.040 |
Why?
| | Neoplasms | 3 | 2001 | 2449 | 0.040 |
Why?
| | Tenofovir | 1 | 2021 | 231 | 0.040 |
Why?
| | Candidiasis | 1 | 1999 | 56 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2019 | 112 | 0.040 |
Why?
| | Triiodothyronine | 1 | 1999 | 44 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 2 | 1999 | 648 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2019 | 67 | 0.040 |
Why?
| | Hemagglutination | 1 | 2018 | 8 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 28 | 0.040 |
Why?
| | Acetates | 1 | 2019 | 100 | 0.040 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2000 | 117 | 0.040 |
Why?
| | Adenine | 1 | 2021 | 256 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 1998 | 42 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2063 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1247 | 0.040 |
Why?
| | Brain Diseases | 1 | 2020 | 136 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 52 | 0.040 |
Why?
| | Delivery, Obstetric | 1 | 2019 | 136 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 1998 | 127 | 0.040 |
Why?
| | Quinazolines | 1 | 2019 | 244 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 62 | 0.040 |
Why?
| | Antibody Specificity | 1 | 1998 | 184 | 0.040 |
Why?
| | Protein Precursors | 1 | 2018 | 128 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 50 | 0.040 |
Why?
| | Shock | 1 | 1998 | 92 | 0.040 |
Why?
| | Sterols | 1 | 2017 | 18 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 22 | 0.030 |
Why?
| | Interleukin-3 | 2 | 1994 | 23 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 411 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3080 | 0.030 |
Why?
| | Autogenic Training | 1 | 1997 | 1 | 0.030 |
Why?
| | Proviruses | 1 | 2017 | 12 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2017 | 62 | 0.030 |
Why?
| | Radioactive Fallout | 1 | 1997 | 1 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1997 | 4 | 0.030 |
Why?
| | Radioactive Hazard Release | 1 | 1997 | 2 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 44 | 0.030 |
Why?
| | Sequence Analysis | 1 | 2017 | 37 | 0.030 |
Why?
| | Relaxation Therapy | 1 | 1997 | 17 | 0.030 |
Why?
| | Power Plants | 1 | 1997 | 8 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 110 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 54 | 0.030 |
Why?
| | Lung Injury | 1 | 2000 | 210 | 0.030 |
Why?
| | Encephalitis | 1 | 1998 | 132 | 0.030 |
Why?
| | Ligands | 1 | 1999 | 621 | 0.030 |
Why?
| | Prevalence | 2 | 2018 | 2553 | 0.030 |
Why?
| | Heart Valves | 1 | 1997 | 42 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1997 | 71 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 1996 | 46 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Body Weight | 1 | 2020 | 939 | 0.030 |
Why?
| | Erythema | 1 | 2016 | 28 | 0.030 |
Why?
| | Up-Regulation | 2 | 2001 | 839 | 0.030 |
Why?
| | Blood Transfusion | 2 | 1995 | 295 | 0.030 |
Why?
| | Registries | 1 | 2024 | 1895 | 0.030 |
Why?
| | Heart Arrest, Induced | 1 | 1995 | 31 | 0.030 |
Why?
| | Thromboembolism | 1 | 1996 | 112 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1998 | 240 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 514 | 0.030 |
Why?
| | Vasodilation | 1 | 1998 | 476 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1994 | 2835 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 347 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2001 | 1367 | 0.030 |
Why?
| | Cross Infection | 1 | 1997 | 217 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1446 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 793 | 0.030 |
Why?
| | Ovulation | 1 | 2015 | 40 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 1997 | 140 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 280 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1839 | 0.030 |
Why?
| | Hypothermia, Induced | 1 | 1995 | 76 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 1995 | 93 | 0.030 |
Why?
| | Rats, Inbred BUF | 1 | 1994 | 1 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 1997 | 283 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 48 | 0.030 |
Why?
| | Quality of Life | 4 | 2000 | 2687 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1996 | 275 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 2 | 2003 | 69 | 0.030 |
Why?
| | Aortic Coarctation | 1 | 1994 | 82 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2001 | 1021 | 0.030 |
Why?
| | Colony-Stimulating Factors | 2 | 1990 | 35 | 0.030 |
Why?
| | Cause of Death | 3 | 2001 | 392 | 0.030 |
Why?
| | Aortic Valve | 1 | 1996 | 347 | 0.030 |
Why?
| | Cardiac Surgical Procedures | 1 | 1998 | 499 | 0.030 |
Why?
| | BK Virus | 1 | 2013 | 13 | 0.030 |
Why?
| | Growth Substances | 2 | 1990 | 150 | 0.030 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 1556 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2001 | 1143 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2276 | 0.030 |
Why?
| | Herpesviridae | 1 | 2012 | 22 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2007 | 768 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1990 | 147 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1996 | 504 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 1992 | 28 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 851 | 0.020 |
Why?
| | Ventricular Function, Left | 1 | 1995 | 527 | 0.020 |
Why?
| | Heart Diseases | 1 | 1995 | 350 | 0.020 |
Why?
| | Spleen | 1 | 1994 | 506 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 736 | 0.020 |
Why?
| | Patient Selection | 1 | 1995 | 662 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 652 | 0.020 |
Why?
| | Histocompatibility Antigens | 1 | 1992 | 107 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1997 | 546 | 0.020 |
Why?
| | Stroke | 1 | 2000 | 1070 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 40 | 0.020 |
Why?
| | Lung Neoplasms | 2 | 2001 | 2342 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 50 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 785 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 496 | 0.020 |
Why?
| | Radiotherapy | 2 | 2005 | 185 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 316 | 0.020 |
Why?
| | Concanavalin A | 1 | 1990 | 75 | 0.020 |
Why?
| | Infant, Premature | 1 | 2014 | 541 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1990 | 149 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 201 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 475 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2010 | 114 | 0.020 |
Why?
| | Anxiety | 1 | 1997 | 962 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2011 | 2871 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1497 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2011 | 361 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 574 | 0.020 |
Why?
| | Herpesvirus 1, Bovine | 1 | 1989 | 3 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 796 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 1990 | 406 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2010 | 329 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1998 | 1097 | 0.020 |
Why?
| | Phylogeny | 1 | 2013 | 849 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 756 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1994 | 436 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 819 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 1999 | 399 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1288 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1994 | 1117 | 0.020 |
Why?
| | Time | 1 | 2007 | 75 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2013 | 671 | 0.020 |
Why?
| | Drug Resistance, Multiple | 1 | 2006 | 25 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2054 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2007 | 254 | 0.020 |
Why?
| | Postoperative Care | 2 | 1999 | 241 | 0.020 |
Why?
| | Templates, Genetic | 1 | 2005 | 61 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1988 | 381 | 0.020 |
Why?
| | Codon | 1 | 2005 | 86 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1432 | 0.010 |
Why?
| | Interleukin-5 | 2 | 1998 | 45 | 0.010 |
Why?
| | DNA Replication | 1 | 2006 | 227 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 372 | 0.010 |
Why?
| | Mice, Transgenic | 2 | 2000 | 2117 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 359 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 398 | 0.010 |
Why?
| | Creatinine | 2 | 1997 | 491 | 0.010 |
Why?
| | Lung | 1 | 1996 | 3927 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 34 | 0.010 |
Why?
| | Endemic Diseases | 1 | 2003 | 31 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2630 | 0.010 |
Why?
| | Peptide Fragments | 2 | 1998 | 692 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2003 | 151 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2005 | 776 | 0.010 |
Why?
| | Cell Differentiation | 3 | 2000 | 1887 | 0.010 |
Why?
| | Bioelectric Energy Sources | 1 | 2001 | 3 | 0.010 |
Why?
| | Electricity | 1 | 2001 | 18 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2001 | 21 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2001 | 94 | 0.010 |
Why?
| | Galvanic Skin Response | 1 | 2001 | 32 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2001 | 26 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2001 | 202 | 0.010 |
Why?
| | Anticoagulants | 2 | 1996 | 636 | 0.010 |
Why?
| | Fingers | 1 | 2001 | 86 | 0.010 |
Why?
| | Melanoma, Experimental | 1 | 2001 | 107 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2001 | 53 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2001 | 72 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2001 | 420 | 0.010 |
Why?
| | Immune Sera | 1 | 2000 | 87 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 443 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2001 | 5439 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1994 | 2056 | 0.010 |
Why?
| | Probability | 1 | 2001 | 305 | 0.010 |
Why?
| | Clone Cells | 1 | 2000 | 262 | 0.010 |
Why?
| | Emergency Treatment | 1 | 2001 | 111 | 0.010 |
Why?
| | Databases as Topic | 1 | 2000 | 59 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 207 | 0.010 |
Why?
| | Students | 1 | 2005 | 579 | 0.010 |
Why?
| | New York | 1 | 2000 | 128 | 0.010 |
Why?
| | Carotid Artery Diseases | 1 | 2000 | 64 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2001 | 470 | 0.010 |
Why?
| | Columbidae | 1 | 1998 | 31 | 0.010 |
Why?
| | Cytochrome c Group | 1 | 1998 | 42 | 0.010 |
Why?
| | Peripheral Vascular Diseases | 1 | 2000 | 101 | 0.010 |
Why?
| | Prognosis | 2 | 1998 | 3773 | 0.010 |
Why?
| | Cardiac Output | 1 | 1999 | 156 | 0.010 |
Why?
| | Life Tables | 1 | 1998 | 18 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 634 | 0.010 |
Why?
| | Cardiotonic Agents | 1 | 1999 | 126 | 0.010 |
Why?
| | Endocardium | 1 | 1998 | 33 | 0.010 |
Why?
| | Aortic Diseases | 1 | 2000 | 113 | 0.010 |
Why?
| | Interleukin-4 | 1 | 1998 | 212 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2000 | 149 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1999 | 370 | 0.010 |
Why?
| | Cell Death | 1 | 1999 | 354 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 202 | 0.010 |
Why?
| | Calcinosis | 1 | 2000 | 231 | 0.010 |
Why?
| | Hypotension | 1 | 1998 | 116 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 198 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1710 | 0.010 |
Why?
| | Ukraine | 1 | 1997 | 7 | 0.010 |
Why?
| | Endocarditis, Bacterial | 1 | 1997 | 42 | 0.010 |
Why?
| | Odds Ratio | 1 | 2000 | 1019 | 0.010 |
Why?
| | Health Care Costs | 1 | 2000 | 367 | 0.010 |
Why?
| | Models, Structural | 1 | 1996 | 39 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2011 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1996 | 45 | 0.010 |
Why?
| | Radiometry | 1 | 1997 | 47 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 1997 | 74 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1998 | 363 | 0.010 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 1996 | 38 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1996 | 66 | 0.010 |
Why?
| | Equipment Failure | 1 | 1996 | 105 | 0.010 |
Why?
| | Urogenital Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
| | Pneumonia, Viral | 1 | 2001 | 339 | 0.010 |
Why?
| | Europe | 1 | 1997 | 363 | 0.010 |
Why?
| | Vital Capacity | 1 | 1996 | 291 | 0.010 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 106 | 0.010 |
Why?
| | Heart Valve Prosthesis | 1 | 1997 | 112 | 0.010 |
Why?
| | Blood Urea Nitrogen | 1 | 1995 | 53 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 1996 | 191 | 0.010 |
Why?
| | Child Development | 1 | 2000 | 457 | 0.010 |
Why?
| | Acute Disease | 1 | 1998 | 978 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 1996 | 510 | 0.010 |
Why?
| | Heart Rate | 1 | 1999 | 802 | 0.010 |
Why?
| | Aortic Aneurysm | 1 | 1995 | 65 | 0.010 |
Why?
| | Hodgkin Disease | 1 | 1997 | 133 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 1197 | 0.010 |
Why?
| | Equipment Design | 1 | 1996 | 513 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 705 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 1092 | 0.010 |
Why?
| | Pain, Postoperative | 1 | 1997 | 233 | 0.010 |
Why?
| | Waiting Lists | 1 | 1996 | 237 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1998 | 704 | 0.010 |
Why?
| | Reoperation | 1 | 1997 | 541 | 0.010 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 1994 | 40 | 0.010 |
Why?
| | Exercise Test | 1 | 1996 | 612 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1994 | 452 | 0.010 |
Why?
| | Myocardium | 1 | 1998 | 978 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 1997 | 310 | 0.010 |
Why?
| | Ventricular Function, Right | 1 | 1995 | 276 | 0.010 |
Why?
| | Patient Compliance | 1 | 1997 | 563 | 0.010 |
Why?
| | Central Nervous System | 1 | 1994 | 253 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 867 | 0.010 |
Why?
| | Smoking | 1 | 2000 | 1499 | 0.010 |
Why?
| | Blood Pressure | 1 | 1998 | 1736 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2000 | 1000 | 0.010 |
Why?
| | Research Design | 1 | 1997 | 1043 | 0.010 |
Why?
| | Head and Neck Neoplasms | 1 | 1995 | 543 | 0.010 |
Why?
| | Lymphocyte Cooperation | 1 | 1990 | 49 | 0.010 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 16 | 0.010 |
Why?
| | Thymectomy | 1 | 1990 | 15 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 1990 | 63 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1990 | 151 | 0.010 |
Why?
| | Immunotherapy | 1 | 1994 | 592 | 0.010 |
Why?
| | Infectious Bovine Rhinotracheitis | 1 | 1989 | 1 | 0.010 |
Why?
| | Phorbol Esters | 1 | 1989 | 15 | 0.000 |
Why?
| | Ionomycin | 1 | 1989 | 25 | 0.000 |
Why?
| | Kidney | 1 | 1997 | 1385 | 0.000 |
Why?
| | Ethers | 1 | 1989 | 16 | 0.000 |
Why?
| | Receptors, Interleukin-2 | 1 | 1989 | 64 | 0.000 |
Why?
| | Isoantigens | 1 | 1988 | 13 | 0.000 |
Why?
| | Cell-Free System | 1 | 1988 | 48 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 2000 | 5384 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 977 | 0.000 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2140 | 0.000 |
Why?
| | Models, Biological | 1 | 1988 | 1722 | 0.000 |
Why?
|
|
Weinberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|